Connect Biopharma Holdings Limited (CNTB) Stock

Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer Steven Chan, an accomplished finance leader, joins Attovia as Chief Financial Officer

Concordia Biotech (CNTB, Financial) saw a significant increase in its stock price, rising by 5.48%. The stock is currently priced at $1.49 per share with a trading volume of 16,435 shares and a turnover rate of 0.03%.

SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases, today reported financial results for the six months ended June 30, 2024 and provided a business update.

SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board).

SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data. The call will feature a discussion with Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and DexCom (DXCM) have performed compared to their sector so far this year.

SAN DIEGO, CA and TAICANG, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the trial results.

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.

Here is how Connect Biopharma Holdings Limited Sponsored ADR (CNTB) and Haemonetics (HAE) have performed compared to their sector so far this year.